A PROMISE FOR A HEALTHIER TOMORROW

PumpinapcoOral disintegrating tablets

Pumpinapco
Pumpinapco
The drug of choice for prevention of gastric or duodenal ulcers associated with non steroidal anti-inflammatory drugs (NSAIDs) therapy in patients at high risk of cardiovascular diseases.
Composition:

A fixed dose combination product contains: Esomeprazole 20 mg & Acetyl salicylic acid 81.1 mg in oral disintegrating tablet.

Propertise:
  • Pumpinapco: is initially used for patients who require Acetyl salicylic acid and Esomeprazole.
  • Pumpinapco: is indicated for patients who require Acetyl salicylic acid for the prevention of cardiovascular diseases (CVD) in combination with Esomeprazole for the prevention of ulcers associated with aspirin use.
  • The proposed dosing regimen involves oral administration of one tablet once daily, and is indicated for adults (18 years and over).
  • Acetyl salicylic acid: inhibits the formation of a precursor for thromboxane A2, which is a short lived inducer of platelets aggregation and a potent vasoconstrictor.
  • Esomeprazole: is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cells where it inhibits the enzyme H+K+ ATPase (the acid pump), which is responsible for both basal and stimulated acid secretion.
Indications:
  • Short term treatment of upper gastrointestinal symptoms associated with non  steroidal anti-inflammatory drugs (NSAIDs) therapy.
  • Healing of gastric ulcers associated with non steroidal anti-inflammatory drugs (NSAIDs) therapy.
  • Prevention of gastric and duodenal ulcers associated with non steroidal anti-nflammatory drugs (NSAIDs) therapy in patients at risk of cardiovascular diseases (CVD).
Dosage & Administration:

One tablet to be taken once daily.